| Name | Title | Contact Details |
|---|
Evelo Therapeutics is the latest breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
NanoCellect`s mission is to facilitate biomedical breakthroughs by making cell analysis and sorting technology more affordable and easier to use. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF`s technology before launching the WOLF (our first product) in 2016. Initial funding of R&D was graciously funded by multiple NIH SBIR grants and contracts and recently backed by FusionX Ventures and other private investors.
Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.
Dren Bio is a San Carlos, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.
BioInnovation Capital invests in the most promising life science companies in residence at premier co-working laboratory facilities where our partners are on-site every day. As the first investment platform to knit together a national network of co-working laboratories, we have a unique lens and an unparalleled position from which to invest. Our partners are located in: Cambridge, MA (BioLabs and LabCentral); Durham, North Carolina (BioLabs North Carolina); San Francisco, and San Diego, CA (BioLabs San Diego). Our perspective is characterized by superb access to key innovators in academia, as well as to the corporate partners who are likely eventual homes for our investments. The geographic nature of innovation hubs and our overlapping network of facilities and resources, supports the formation of stellar companies from the most powerful universities, research institutions, hospitals and corporations in our sector.